

## Special Issue

# Treatment Options and Risk Factors for Pancreatic Neuroendocrine Neoplasms

### Message from the Guest Editors

Pancreatic neuroendocrine neoplasms (Pan-NENs) are considered rare tumors with a wide spectrum of hormonal secretion, or if “inactive” may have indolent behavior, largely dependent on the tumor extension, grading, inherited presence of gene mutations, expression of somatostatin receptors, and other factors that may influence the indication and results of the treatment options. This Special Issue will highlight the main strengths and limitations of the management of Pan-NENs, ranging from the diagnosis to the response to therapy, and investigate the emerging role of new therapeutic approaches.

---

### Guest Editors

Prof. Dr. Anna Caterina Milanetto

Pancreatic and Endocrine Digestive Surgical Unit, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy

Prof. Dr. Claudio Pasquali

Pancreatic and Endocrine Digestive Surgical Unit, Department of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Via Giustiniani 2, 35128 Padova, Italy

---

### Deadline for manuscript submissions

closed (3 April 2026)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/215481](https://mdpi.com/si/215481)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)